Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High frequency of the HLA-G*01:05N null allele in Beninese populations and its potential impact on reduced soluble HLA-G expression.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2026

Same author

The plague of 1720 and migration in Martigues (France) in the 17th and 18th centuries.

PloS one·2026

Same author

African harps as units of cultural evolution: a cladistic analysis on their morphology.

Evolutionary human sciences·2025

Same author

Human genetic structure in Northwest France provides new insights into West European historical demography.

Nature communications·2024

Same author

Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.

The British journal of dermatology·2023

Same author

Combined polymorphisms involving the IgG heavy chain and Fc gamma receptors among Fulani and non-Fulani in Benin: implications for the natural protection of young Fulani against Plasmodium falciparum malaria infections.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2023

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Data-mining methods as useful tools for predicting individual drug response: application to CYP2D6 data.

Audrey Sabbagh¹, Pierre Darlu

¹Unité de Recherche en Génétique Epidémiologique et Structure des Populations Humaines, INSERM U535, Villejuif, France. sabbagh@vjf.inserm.fr

|October 24, 2006

Summary

Identifying key genetic markers for drug response prediction, like CYP2D6 metabolizer status, can be simplified. Data-mining tools efficiently pinpoint essential polymorphisms, reducing genotyping efforts for personalized medicine.

Related Experiment Videos

Last Updated: Jul 19, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Pharmacogenetics
Genetics
Computational Biology

Background:

Predicting drug response requires identifying informative genetic markers.
High dimensionality in genotype data necessitates efficient selection methods.

Purpose of the Study:

To evaluate pattern recognition methods for selecting informative CYP2D6 gene markers.
To predict CYP2D6 metabolizer status using identified polymorphisms.

Main Methods:

Explored decision trees, random forests, artificial neural networks, and multifactor dimensionality reduction (MDR).
Performed marker selection across eight diverse ethnic populations.

Main Results:

A reduced set of polymorphisms accurately predicts CYP2D6 metabolic phenotype.
Strong CYP2D6 haplotype block structure facilitates marker reduction.
MDR and neural networks performed best, yielding similar results.

Conclusions:

Data-mining tools like MDR and neural networks are effective for marker selection.
These methods enhance genotyping test efficiency in pharmacogenetics.
Enables pre-screening for personalized therapy with minimal genotyping.